COMPASS THERAPEUTICS INC (CMPX:NASDAQ)
$2.04 0.03 (1.4925%)
Analysed COMPASS THERAPEUTICS INC (CMPX:NASDAQ) News Sources
Compass Therapeutics’s stock crashes after OS miss in BTC trial
28-04-2026
clinicaltrialsarena.com
Micron initiated, Rambus downgraded: Wall Street's top analyst calls
28-04-2026
yahoo.com
Does Compass Therapeutics' (CMPX) Biliary Cancer Data Hint At A Broader Pipeline Re‑Rating Opportunity?
29-04-2026
yahoo.com
Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update
05-05-2026
yahoo.com
Canaccord Maintains Buy Rating on Compass Therapeutics (CMPX)
05-05-2026
yahoo.com
Compass Therapeutics to Participate in Upcoming May Investor Events
12-05-2026
yahoo.com
Compass Therapeutics (CMPX) Reports Q1 2026 Net Loss of $18.3M
18-05-2026
yahoo.com
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
21-05-2026
yahoo.com
Compass Therapeutics to Participate in Upcoming June Investor Events
28-05-2026
yahoo.com
Compass Therapeutics Eyes FDA Path After Tovecimig Trial Win
08-06-2026
marketbeat.com
What is the current price of COMPASS THERAPEUTICS INC (CMPX:NASDAQ)?
The current price of COMPASS THERAPEUTICS INC (CMPX:NASDAQ) is $2.04.
COMPASS THERAPEUTICS INC (CMPX:NASDAQ) absolute price change since previous trading day?
The absolute price change of COMPASS THERAPEUTICS INC (CMPX:NASDAQ) since the previous trading day is $0.03.
COMPASS THERAPEUTICS INC (CMPX:NASDAQ) percentage price change since previous trading day?
The percentage price change of COMPASS THERAPEUTICS INC (CMPX:NASDAQ) since the previous trading day is 1.4925%.
What is the most recent average sentiment score for COMPASS THERAPEUTICS INC (CMPX:NASDAQ)?
The most recent average sentiment score for COMPASS THERAPEUTICS INC (CMPX:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for COMPASS THERAPEUTICS INC (CMPX:NASDAQ)?
The most recent sentiment for COMPASS THERAPEUTICS INC (CMPX:NASDAQ) is .
SEC-8K** Filing Available For COMPASS THERAPEUTICS INC (CMPX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.